Ocular Therapeutix Inc (OCUL) Expected to Announce Quarterly Sales of $450,000.00
Wall Street analysts predict that Ocular Therapeutix Inc (NASDAQ:OCUL) will announce sales of $450,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Ocular Therapeutix’s earnings. The lowest sales estimate is $350,000.00 and the highest is $500,000.00. Ocular Therapeutix reported sales of $490,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 8.2%. The business is scheduled to issue its next earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Ocular Therapeutix will report full year sales of $1.93 million for the current financial year, with estimates ranging from $1.84 million to $1.99 million. For the next fiscal year, analysts expect that the firm will report sales of $18.36 million, with estimates ranging from $9.03 million to $27.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Ocular Therapeutix.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). Ocular Therapeutix had a negative return on equity of 133.73% and a negative net margin of 2,822.15%. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.45 million.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC raised its stake in shares of Ocular Therapeutix by 24.1% during the third quarter. Teachers Advisors LLC now owns 67,202 shares of the biopharmaceutical company’s stock valued at $462,000 after purchasing an additional 13,061 shares in the last quarter. Man Group plc bought a new stake in shares of Ocular Therapeutix during the third quarter valued at about $3,461,000. Dimensional Fund Advisors LP bought a new stake in shares of Ocular Therapeutix during the third quarter valued at about $200,000. Trexquant Investment LP bought a new stake in shares of Ocular Therapeutix during the third quarter valued at about $139,000. Finally, BlackRock Inc. raised its stake in shares of Ocular Therapeutix by 16.6% during the third quarter. BlackRock Inc. now owns 2,292,263 shares of the biopharmaceutical company’s stock valued at $15,770,000 after purchasing an additional 326,381 shares in the last quarter. Institutional investors and hedge funds own 52.15% of the company’s stock.
Ocular Therapeutix stock traded up $0.12 during mid-day trading on Friday, reaching $5.23. The company’s stock had a trading volume of 4,932 shares, compared to its average volume of 412,681. The company has a market cap of $215.34 million, a PE ratio of -2.36 and a beta of 1.55. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.35 and a quick ratio of 4.34. Ocular Therapeutix has a twelve month low of $3.30 and a twelve month high of $8.28.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Featured Story: Outstanding Shares and The Effect on Share Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.